Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Equity (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Return on Equity for 7 consecutive years, with 0.46% as the latest value for Q3 2025.

  • For Q3 2025, Return on Equity changed N/A year-over-year to 0.46%; the TTM value through Sep 2025 reached 0.46%, changed N/A, while the annual FY2023 figure was 0.67%, 155.0% up from the prior year.
  • Return on Equity hit 0.46% in Q3 2025 for Cyclerion Therapeutics, down from 0.36% in the prior quarter.
  • Across five years, Return on Equity topped out at 1.44% in Q2 2024 and bottomed at 3.64% in Q1 2023.
  • Average Return on Equity over 5 years is 0.99%, with a median of 1.06% recorded in 2021.
  • Year-over-year, Return on Equity tumbled -236bps in 2023 and then surged 477bps in 2024.
  • Cyclerion Therapeutics' Return on Equity stood at 1.06% in 2021, then tumbled by -149bps to 2.62% in 2022, then soared by 123bps to 0.61% in 2023, then soared by 137bps to 1.44% in 2024, then tumbled by -132bps to 0.46% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.46%, 0.36%, and 0.17% for Q3 2025, Q2 2025, and Q1 2025 respectively.